Chris O’Brien Lifehouse

Futó vizsgálatok

• Toboroz

  Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy

  NCT07576335· 2. fázis· Forrás

• Toboroz

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

  NCT07659782· 2. fázis· Forrás

• Toboroz

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

  NCT07527858· 2. fázis· Forrás

• Még nem toboroz

  Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

  NCT07527819· Forrás

• Toboroz

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  NCT07288177· 2. fázis· Forrás

• Toboroz

  A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

  NCT07235293· 2. fázis· Forrás

• Toboroz

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· 2/3. fázis· Forrás

• Toboroz

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· 3. fázis· Forrás

• Toboroz

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  NCT07166094· 3. fázis· Forrás

• Toboroz

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· 2. fázis· Forrás

• Toboroz

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· 3. fázis· Forrás

• Toboroz

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Forrás

• Toboroz

  A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

  NCT06855771· 2. fázis· Forrás

• Toboroz

  A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  NCT07060807· 3. fázis· Forrás

• Toboroz

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· 3. fázis· Forrás

• Toboroz

  A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

  NCT06905197· 1. fázis· Forrás

• Toboroz

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· 3. fázis· Forrás

• Toboroz

  A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

  NCT06892548· 1/2. fázis· Forrás

• Toboroz

  A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  NCT06914128· 1/2. fázis· Forrás

• Toboroz

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· 2/3. fázis· Forrás

• Toboroz

  A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

  NCT06789172· 1. fázis· Forrás

• Toboroz

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· 3. fázis· Forrás

• Toboroz

  A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  NCT06667908· 2. fázis· Forrás

• Toboroz

  A Study of DM005 in Patients With Advanced Solid Tumors

  NCT06515990· 1/2. fázis· Forrás

• Toboroz

  Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

  NCT06441747· 2. fázis· Forrás

• Toboroz

  Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

  NCT07377747· Forrás

• Fut, nem toboroz

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

  NCT06486441· 3. fázis· Forrás

• Toboroz

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· 3. fázis· Forrás

• Toboroz

  A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  NCT06203210· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT06318273· 1. fázis· Forrás

• Toboroz

  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  NCT06172478· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

  NCT06003231· 2. fázis· Forrás

• Toboroz

  Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

  NCT06084481· 1. fázis· Forrás

• Fut, nem toboroz

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

  NCT05794906· 3. fázis· Forrás

• Toboroz

  Metastatic Leiomyosarcoma Biomarker Protocol

  NCT05653388· Forrás

• Fut, nem toboroz

  Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

  NCT05599984· 1. fázis· Forrás

• Toboroz

  Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

  NCT05393791· 2. fázis· Forrás

• Toboroz

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

  NCT05388669· 3. fázis· Forrás

• Fut, nem toboroz

  HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

  NCT05338970· 3. fázis· Forrás

• Toboroz

  Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

  NCT05025813· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· 3. fázis· Forrás

• Toboroz

  A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

  NCT05118789· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study of AL102 in Patients With Progressing Desmoid Tumors

  NCT04871282· 2/3. fázis· Forrás

• Fut, nem toboroz

  A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

  NCT04974398· 3. fázis· Forrás

• Toboroz

  Personalised Immunotherapy Platform

  NCT06536257· Forrás

• Fut, nem toboroz

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· 3. fázis· Forrás

• Fut, nem toboroz

  HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

  NCT04619004· 2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák17 toboroz
• Vastagbélrák8 toboroz
• Fej-nyaki daganatok7 toboroz
• Petefészekrák7 toboroz
• Szarkóma6 toboroz
• Gyermekkori daganatok5 toboroz
• Hasnyálmirigyrák4 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Méhtestrák3 toboroz
• Prosztatarák3 toboroz
• Tripla negatív emlőrák3 toboroz
• Máj- és epeúti rák2 toboroz
• Melanóma2 toboroz
• Áttétes emlőrák1 toboroz
• Glioblasztóma1 toboroz
• Hólyagrák1 toboroz
• Méhnyakrák1 toboroz
• Pajzsmirigyrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· 2. fázis· Forrás

• Leállították

  Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT04918810· 2. fázis· Forrás

• Leállították

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· 2/3. fázis· Forrás

• Lezárult

  A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT05252364· 1. fázis· Forrás

• Lezárult

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· 3. fázis· Forrás

• Lezárult

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· 3. fázis· Forrás

• Leállították

  A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

  NCT04432207· 1. fázis· Forrás

• Toboroz

  Study of PF-07248144 in Advanced or Metastatic Solid Tumors

  NCT04606446· 2. fázis· Forrás

• Leállították

  Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

  NCT04585815· 1/2. fázis· Forrás

• Leállították

  Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

  NCT04316013· 3. fázis· Forrás

• Lezárult

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· 3. fázis· Forrás

• Toboroz

  A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

  NCT05999994· 2. fázis· Forrás

• Lezárult

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· 2. fázis· Forrás

• Lezárult

  Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

  NCT03710876· 3. fázis· Forrás

• Lezárult

  Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

  NCT02662062· 2. fázis· Forrás

• Lezárult

  A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

  NCT02601950· 2. fázis· Forrás

• Lezárult

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· 3. fázis· Forrás

• Lezárult

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· 3. fázis· Forrás

Vizsgálati helyszínek

• Chris O'Brien Lifehouse73 vizsgálat
• Chris O'Brien Lifehouse /ID# 2132361 vizsgálat
• Chris O'Brien Lifehouse /ID# 2590871 vizsgálat
• Chris O'Brien Lifehouse /ID# 2617311 vizsgálat
• Chris O'Brien Lifehouse /ID# 2627651 vizsgálat
• Chris O'Brien Lifehouse (Site#0302)1 vizsgálat
• Chris O'Brien Lifehouse (Site 1206)1 vizsgálat
• Chris O'Brien Lifehouse (Site 2302)1 vizsgálat
• Chris O'Brien Lifehouse (Site 3000)1 vizsgálat
• The Chris O'Brien Lifehouse2 vizsgálat
• Chris O'Brien Lifehouse10 vizsgálat
• Chris O'Brien Lifehouse /ID# 2763371 vizsgálat

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Fej-nyaki daganatok20 munka · 9 vizsgálat